442TiP A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)

A comprehensive overview of the molecular features and therapeutic targets in BRAFV600E‐mutant colorectal cancer

“…Furthermore, for patients with BRAF V600E ‐mutant CRLM, those with node‐negative primary tumours and Carcinoembryonic Antigen (CEA) ≤ 200 µg/L exhibited a lower probability of postoperative recurrence and enjoyed prolonged survival benefits 121 . At present, there are prospective clinical trials aimed at assessing whether the administration of BRAF inhibitors as neoadjuvant targeted therapy can enhance the likelihood and efficacy of curative surgery for BRAF V600E ‐mutant patients with unresectable mCRC 122 (Table 2).…”